Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (Nasdaq: KPTI) announces the appointment of Elhan Webb as Senior Vice President of Investor Relations, effective March 14, 2022. Webb brings over 20 years of experience in investor relations and business development, having held roles at Rubius Therapeutics and Radius Health. CEO Richard Paulson emphasized her expertise in building investor relations to enhance Karyopharm's visibility in the market. The company is known for its lead compound, XPOVIO®, which is approved in multiple oncology indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced its senior management will engage in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 a.m. ET in Miami, Florida. This event highlights Karyopharm's pioneering role in developing cancer therapies, particularly with its lead product, XPOVIO® (selinexor), which is approved for multiple oncology indications.
Investors can access a live webcast of this chat and related slides via the company's investor site, with a replay available for 90 days post-event.
Karyopharm Therapeutics (KPTI) provided an update on its discussions with the FDA regarding its supplemental New Drug Application (sNDA) for selinexor, intended for advanced endometrial cancer. The FDA indicated that existing SIENDO study results might not justify an sNDA approval. Differing views on the study's clinical significance led to plans for a new randomized clinical trial focusing on p53 wild-type patients, with top-line data expected in H1 2024. The SIENDO study results will be presented at upcoming oncology conferences in March 2022.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on February 28, 2022, the approval of stock options for 168,500 shares and 112,200 restricted stock units (RSUs) to nine new employees. These awards are part of the 2022 Inducement Stock Incentive Plan and serve as an employment inducement per Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.33, vesting over four years, with specific conditions for immediate exercise upon a change in control or termination for good reason.
Karyopharm Therapeutics (Nasdaq: KPTI) announced key changes in its clinical leadership team on February 22, 2022. Patricia Judson, M.D., joins as Senior VP of Medical Strategy, and Stuart Poulton as Senior VP of Strategy and Portfolio Management. Jatin Shah, M.D., has stepped down as Chief Medical Officer but will remain in an advisory role. Richard Paulson, CEO, highlighted that the new leaders bring extensive oncology and pharmaceutical experience, which will aid the company in advancing its drug pipeline addressing significant unmet medical needs.
Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast will be available in the Investor section of their website, with replays accessible for 90 days. Karyopharm specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, including its approved drug XPOVIO®. The company's pipeline targets multiple high unmet need cancer indications.
Karyopharm Therapeutics (Nasdaq: KPTI) reported strong financial results for Q4 2021, with net product revenue of $29.8 million, a 47% increase year-over-year. Total revenue for 2021 reached $209.8 million, up from $108.1 million in 2020. They achieved significant milestones, including a commercialization partnership with Menarini and positive data from the SIENDO study on selinexor. However, the company reported a net loss of $124.1 million for 2021. For 2022, Karyopharm expects XPOVIO revenue between $135 million and $145 million.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive results from its Phase 3 SIENDO study on selinexor for patients with advanced or recurrent endometrial cancer. The study involved 263 patients and achieved a median progression-free survival (PFS) of 5.7 months with selinexor, compared to 3.8 months for placebo, marking a 50% improvement. The drug showed a 30% reduction in disease progression risk. Particularly, patients with wild-type p53 saw a median PFS of 13.7 months. Karyopharm plans to submit a supplemental New Drug Application to the FDA in H1 2022.
Karyopharm Therapeutics (KPTI) will report its fourth quarter and full year 2021 financial results on February 8, 2022. Management will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and updates. Karyopharm is known for its novel cancer therapies, including the first-in-class XPO1 inhibitor, XPOVIO®, and has a focused pipeline targeting high unmet needs in cancer treatments. Interested parties can access the call via phone or a live audio webcast on the company's website.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 124,500 shares to 15 newly-hired employees, effective January 31, 2022. The exercise price is set at $8.90 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after one year and the remainder monthly. The options are also subject to immediate exercise if the employee's role is terminated without cause within a year following a 'change in control.' This move aligns with Nasdaq rules for inducements to new hires.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
